I agree its more likely to get up on the exotics .. personally I think thats what the qtrly inferred. I think numericalally you're massively understating the value on those carve out even on stand alone basis.
To Lux's view, a lot of that comes back to negotiations and sometimes you need to get out of bed on the wrong side to get them right.
Regardless, other factors aside from incumbency will play into the C19 or C# whatever future meds
Tackling this stock subtlety and on upside is the way to bring it down.. and also a good way to be 'caught short'.
If it gets take off, its broadspectrum and durable, low cost etc... I personally see you retelling your 'missed the train' story.
Like many other stocks like this rationally postiion sizing makes sense to me
